Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature
- PMID: 26656906
- DOI: 10.1016/j.autrev.2015.11.009
Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature
Abstract
The antiphospholipid syndrome (APS) is defined by the occurrence of venous and arterial thromboses and recurrent fetal losses, frequently accompanied by a moderate thrombocytopenia, in the presence of antiphospholipid antibodies (aPL), namely lupus anticoagulant (LA), anticardiolipin antibodies (aCL), or anti-β2 glycoprotein-I (β2GPI) antibodies. The current mainstay of treatment for thrombotic APS is heparin followed by long-term anticoagulation, while in obstetric APS, the accepted first-line treatment consists in low-dose aspirin (LDA) plus prophylactic unfractionated or low-molecular-weight heparin (LMWH). Recently, new emerging treatment modalities, including intravenous immunoglobulins (IVIG), have been implemented to manage APS refractory to conventional therapy. The objective of this review is to summarize the currently available information on the IVIG therapy in APS, focusing on the use of IVIG in the obstetric form, CAPS and on primary or secondary thromboprophylaxis. We analyzed 35 studies, reporting the effects of IVIG in APS patients, and we discussed their results. IVIG in obstetric APS seem to be very useful in selected situations (patients not responsive to the conventional treatment, concomitant autoimmune manifestations or infections or patients in whom anticoagulation is contraindicated). IVIG treatment represents an important component of the combination therapy of CAPS and they could be useful, in addition to the standard therapy, to prevent recurrent thrombosis in APS patients refractory to conventional anticoagulant treatment. Anyway, in some cases we also found controversial results that claim the need of further well-designed studies to definitely state the efficacy and tolerability of IVIG in CAPS, obstetric and non-APS.
Keywords: Antiphospholipid syndrome; Catastrophic antiphospholipid syndrome; Intravenous immunoglobulin; Obstetric antiphospholipid syndrome; Prevention of thromboses.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Intravenous immunoglobulin therapy of antiphospholipid syndrome.Rheumatology (Oxford). 2000 Apr;39(4):421-6. doi: 10.1093/rheumatology/39.4.421. Rheumatology (Oxford). 2000. PMID: 10817776 Review.
-
Intravenous immunoglobulin therapy in antiphospholipid syndrome.Clin Rev Allergy Immunol. 2005 Dec;29(3):229-36. doi: 10.1385/CRIAI:29:3:229. Clin Rev Allergy Immunol. 2005. PMID: 16391398 Review.
-
Intravenous immunoglobulin for the secondary prevention of stillbirth in obstetric antiphospholipid syndrome: A case series and systematic review of literature.Autoimmun Rev. 2020 Sep;19(9):102620. doi: 10.1016/j.autrev.2020.102620. Epub 2020 Jul 16. Autoimmun Rev. 2020. PMID: 32682986
-
Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy.Clin Exp Rheumatol. 2013 Nov-Dec;31(6):877-82. Epub 2013 Aug 2. Clin Exp Rheumatol. 2013. PMID: 23985161
-
Antiphospholipid syndrome.Thromb Res. 2017 Mar;151 Suppl 1:S43-S47. doi: 10.1016/S0049-3848(17)30066-X. Thromb Res. 2017. PMID: 28262233 Review.
Cited by
-
Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.Antibodies (Basel). 2023 Mar 2;12(1):20. doi: 10.3390/antib12010020. Antibodies (Basel). 2023. PMID: 36975367 Free PMC article. Review.
-
Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020-1. Online ahead of print. Int J Hematol. 2025. PMID: 40471516
-
Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.Clin Rev Allergy Immunol. 2017 Aug;53(1):14-27. doi: 10.1007/s12016-016-8568-1. Clin Rev Allergy Immunol. 2017. PMID: 27342459 Review.
-
Pregnancy Outcome in Women with Obstetric and Thrombotic Antiphospholipid Syndrome-A Retrospective Analysis and a Review of Additional Treatment in Pregnancy.Clin Rev Allergy Immunol. 2017 Aug;53(1):54-67. doi: 10.1007/s12016-016-8569-0. Clin Rev Allergy Immunol. 2017. PMID: 27395067
-
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.Int J Mol Sci. 2020 May 10;21(9):3377. doi: 10.3390/ijms21093377. Int J Mol Sci. 2020. PMID: 32397684 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous